Across a broad array of murine cancers such as lung, ovarian, renal cell, triple-negative breast, and colon cancer, and also in melanoma and glioblastoma models, LXRβ treatment promotes partial or complete tumour regression and a reduction in both tumour-infiltrating and circulating PMN-MDSCs and M-MDSCs [204]. The gene discussed is NR1H2; the disease is cancer.